Aflatoxin and liver cancer.

This chapter reviews the data that have been accumulated implicating aflatoxin ingestion as an important risk factor in the aetiology of hepatocellular carcinoma (HCC). Numerous epidemiological studies have observed a correlation between areas of high aflatoxin exposure and a high incidence of HCC. The use of experimental models and specific biomarkers for aflatoxin exposure, such as urinary metabolites or aflatoxin adducts, have validated these findings. Ongoing clinical trials in Qidong, China, have indicated that oltipraz, a chemopreventive agent, can lower the biologically effective dose of aflatoxins by decreasing the metabolism of aflatoxin to its carcinogenic form and increasing the detoxification pathways of these metabolites. Intervention with chemicals such as these, alongside hepatitis B virus immunization programmes and improved storage conditions of staple foods, are prevention measures that can be undertaken to reduce the incidence of HCC in high-risk regions.

[1]  I. Purchase,et al.  Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. , 1985, British Journal of Cancer.

[2]  A. Muñoz,et al.  Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. , 1995, Carcinogenesis.

[3]  P. Cerutti,et al.  Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Lotan,et al.  Biomarkers as intermediate end points in chemoprevention trials. , 1990, Journal of the National Cancer Institute.

[5]  S R Tannenbaum,et al.  Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. , 1987, Carcinogenesis.

[6]  A. Hall,et al.  Aflatoxin-albumin adducts in human sera from different regions of the world. , 1990, Carcinogenesis.

[7]  S. Thorgeirsson,et al.  Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. , 1994, Cancer research.

[8]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[9]  L. Salamat,et al.  A case-control dietary study of primary liver cancer risk from aflatoxin exposure. , 1982, International journal of epidemiology.

[10]  T. Campbell,et al.  Nonassociation of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. , 1990, Cancer research.

[11]  J. Groopman,et al.  Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. , 1992, Carcinogenesis.

[12]  John Davis Groopman,et al.  The toxicology of aflatoxins: human health, veterinary and agricultural significance. , 1993 .

[13]  J. Kaldor,et al.  Aflatoxin exposure, hepatitis b virus infection and liver cancer in swaziland , 1987, International journal of cancer.

[14]  J. Groopman,et al.  Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. , 1992, Cancer research.

[15]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[16]  C. Harris,et al.  An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. , 1996, Carcinogenesis.

[17]  H. Whittle,et al.  Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  C. Wild,et al.  Liver cancer in Thailand. II. A case‐control study of hepatocellular carcinoma , 1991, International journal of cancer.

[19]  J. Miller,et al.  Base substitution mutations induced by metabolically activated aflatoxin B1. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Henderson,et al.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  C. Harris,et al.  p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. , 1996, Environmental health perspectives.

[22]  C. J. Chen,et al.  p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. , 1997, Cancer research.

[23]  A. Riggs,et al.  The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts , 1998, Oncogene.

[24]  J. Groopman,et al.  Molecular dosimetry in rat urine of aflatoxin-N7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and immunoaffinity/high performance liquid chromatography. , 1992, Cancer research.

[25]  P. Cerutti,et al.  Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. , 1994, Cancer research.

[26]  L. Magder,et al.  Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure? , 1997, Environmental health perspectives.

[27]  D. Hsieh,et al.  Recent aflatoxin exposure and mutation at codon 249 of the human p53 gene: lack of association. , 1995, Food additives and contaminants.

[28]  B. Henderson,et al.  Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. , 1989, Cancer research.

[29]  K. Kinzler,et al.  Carcinogens leave fingerprints , 1992, Nature.

[30]  A. E. Rogers,et al.  Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. , 1991, Cancer research.

[31]  Y. Cao,et al.  Aberrations of p53 gene in human hepatocellular carcinoma from China. , 1993, Carcinogenesis.

[32]  C. Harris,et al.  Geographic variation of p53 mutational profile in nonmalignant human liver. , 1994, Science.

[33]  C. Challen,et al.  Analysis of the p53 tumor‐suppressor gene in hepatocellular carcinomas from britain , 1992, Hepatology.

[34]  Chien-Jen Chen,et al.  Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan , 1996, International journal of cancer.

[35]  J. Essigmann,et al.  Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. J. Chen,et al.  Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. , 1997, Journal of hepatology.

[37]  H. Autrup,et al.  Detection of putative adduct with fluorescence characteristics identical to 2,3-dihydro-2-(7'-guanyl)-3-hydroxyaflatoxin B1 in human urine collected in Murang'a district, Kenya. , 1983, Carcinogenesis.

[38]  Yeh Fu-Sun,et al.  Epidemiology and early diagnosis of primary liver cancer in China. , 1986 .

[39]  C. Wild,et al.  Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. , 1990, Cancer research.

[40]  A. Muñoz,et al.  Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. , 1999, Journal of the National Cancer Institute.

[41]  J. Essigmann,et al.  Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. , 1981, Cancer research.

[42]  A. Rashid,et al.  Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations , 1999, British Journal of Cancer.

[43]  S. Tannenbaum,et al.  Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. , 1988, Carcinogenesis.

[44]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[45]  H. Autrup,et al.  Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. , 1987, Cancer research.

[46]  H. Whittle,et al.  Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  C. Cartiglia,et al.  Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[48]  J. Groopman,et al.  Epidemiology of human aflatoxin exposures and their relationship to liver cancer. , 1996, Progress in clinical and biological research.

[49]  A. Puisieux,et al.  Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.

[50]  A. Muñoz,et al.  Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  B. Henderson,et al.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.

[52]  B. Yvonnet,et al.  High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. , 1993, British Journal of Cancer.

[53]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.